Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment

Summary

Recombinant human erythropoietin (r-HuEpo) has been used to treat renal anemia and improve morbidity and mortality in chronic kidney disease. Subcutaneous use of r-HuEpo causes immunogenicity and develops anti-r-HuEpo associated pure red cell aplasia (PRCA). The treatment of anti-r-HuEpo associated pure red cell aplasia is controversial. The investigators aim to evaluate the treatment for anti-r-HuEpo associated pure red cell aplasia in this study.

Timeline

Start

2009-01

Primary completion

2012-01

Completion

2012-01

Drugs

Indications